PTO/SB/82 (01-06)
Approved for use through 12/31/2008, OMB 0651-0035
redemark Officer U.S. DEPARTMENT OF COMMISSION

Linder the Paperwork Reduction Act of 1995, no persons are required in re-	espend to a collection of information up	eas it displays a valid OMS control number.
	Application Number	09/496,932
REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS	Filing Date	February 2, 2000
	First Named Inventor	Tamotsu SUZUKI
	Art Unit	2684
	Examiner Name	P. Tran
	Attorney Docket Number	40404.84

A Power of Attorney is submi	itted herewith.	
OR I hereby appoint the practition	mers associated with the Customer Number.	54068
Please change the correspon The address associated Customer Number: OR	dence address for the above-identified applicati with 54088	ion to:
Firm or Individual Name		
Address		
City	State	Zip
Country		
Telephone	Email	
I am the: Applicant/inventor. Assignee of record of the e	ntire interest. See 37 CFR 3.71. 73(b) is enclosed. (Form PTO/SB/96)	
		·
Statement under 37 CFR 3.	NATURE of Applicant or Assignee of Recor	đ
Statement under 37 CFR 3.	NATURE of Applicant or Assignee of Recon	đ
Statement under 37 CFR 3.	NATURE of Applicant or Assignee of Recon Analysis an Applicant or Assignee of Recon language Intellectual Property Div., Rohm Co., Ltd.	d

The collection of information is required by 30 CFR 1.36. This information is required to dollar or relatin a benefit by the public whitm a to fine (and by the LISPTO to proceed) an application. Confidentiality is governed by 30 LISC, 1.22 and 37 CFR 1.11 and 1.14. This obtained is selected to lists 3 minutes to complete, on the control of the confidence of the confidence of the control of the

Privacy Act Statement

The Phacy Act of 1974 (P.L. 83-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S. C. (26)(2); (2) turnishing of the information signal distribution and (3) the principal purpose for which the information is used by the U.S. Patient and Trademark Office is to process and/or exemine your submission related to a patient application or patient. If you do not furnish the requested information, the U.S. Patient and Trademark Office are you to be able to process and/or examine your submission, which may result in termination of proceedings or abandoment of the application or expiration of the patient.

The information provided by you in this form will be subject to the following routine uses:

- 1. The Information on this form will be treated conflicientially to the extent allowed under the Freedom of Information Act (§ U.S.C. \$52) and the Privacy Act (§ U.S. \$522). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, megistrate, or administrative tribunal, including disclosures to opposing coursel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 5528(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the international Burseau of the World Intellectual Property Organization pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 216(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management, practices and programs, under authority of 44 U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (#e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became shandroad or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued native.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State,
 or local law enforcement agency, if the USPTO becomes aware of a violation or potential
 violation of law or regulation.